Detalles de la búsqueda
1.
Economic costs of chemotherapy-induced febrile neutropenia among patients with non-Hodgkin's lymphoma in European and Australian clinical practice.
BMC Cancer
; 12: 362, 2012 Aug 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-22913768
2.
Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma.
Support Care Cancer
; 20(3): 647-52, 2012 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-22101611
3.
Validation of a guideline-based composite outcome assessment tool for asthma control.
Respir Res
; 8: 26, 2007 Mar 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-17376233
4.
The use of granulocyte colony stimulating factor (G-CSF) and management of chemotherapy delivery during adjuvant treatment for early-stage breast cancer--further observations from the IMPACT solid study.
Breast
; 25: 27-33, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26801413
5.
External validation of a risk model of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma.
Leuk Lymphoma
; 54(11): 2426-32, 2013 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-23452152
6.
Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
Clin Lymphoma Myeloma Leuk
; 12(5): 297-305, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23040435
7.
The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practice.
Leuk Res
; 36(5): 548-53, 2012 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-22385870
8.
Importance of granulocyte colony-stimulating factor prophylaxis in therapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone given every 14 days for diffuse large B-cell lymphoma in routine clinical practice.
Leuk Lymphoma
; 53(5): 982-4, 2012 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-22111969
Resultados
1 -
8
de 8
1
Próxima >
>>